Epitopoietic Research Corporation (ERC) has developed an innovative immunotherapy approach specifically targeting brain cancers, particularly high-grade gliomas such as glioblastoma multiforme. Their flagship product, GLIOVAC/ERC1671/SITOIGANAP, is a therapeutic vaccine that utilizes a combination of autologous tumor cells (derived from the patient) and allogeneic tumor cells (from multiple donors). This unique formulation aims to stimulate the patient's immune system to recognize and attack cancer cells, potentially leading to their destruction. By leveraging the body's natural immune response, ERC's technology seeks to improve both the efficacy of treatment and the quality of life for patients, minimizing the adverse effects commonly associated with traditional cancer therapies.

In addition to its focus on brain cancer, ERC is also exploring the application of its immunotherapy technologies to combat emerging infectious diseases, including SARS-CoV-2 and Ebola. The company is actively engaged in clinical trials to assess the effectiveness of its therapies, with a particular emphasis on patients who have not responded to conventional treatments. ERC's commitment to scientific innovation and collaboration with leading clinicians worldwide positions it as a promising player in the biopharmaceutical landscape, aiming to provide new therapeutic alternatives for patients facing dire prognoses.

Belgium

Immunotherapy is a Bio-pharmaceutical company that develops a safe and highly effective approach for cancer treatment, focusing on Glioblastoma multiforme using its patented Gliovac/ERC1671.

Epitopoietic Research Corporation

Company Details